NCT00870168已完成不适用
Modifications of Hormone Receptors and Biological Parameters of Metastatic Breast Cancer Treated With First-line Chemotherapy. Prospective Biological Study.
Centre Jean Perrin2 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2006年1月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 60
- 试验地点
- 2
- 主要终点
- Changes in hormone receptor expression
研究概览
简要总结
RATIONALE: Studying biopsy samples in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This clinical trial is studying biopsy samples in women who are receiving first-line chemotherapy for metastatic breast cancer.
详细描述
OBJECTIVES:
Primary
- Evaluate the effect of first-line chemotherapy on expression of hormone receptors and biomarkers in women with metastatic breast cancer.
Secondary
- Assess changes in HER1 and HER2 expression during treatment.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Histologically confirmed adenocarcinoma of the breast
- •Metastatic disease
- •No inflammatory breast cancer
- •Measurable disease according to RECIST criteria
- •Hormone receptor status:
- •Estrogen receptor- and/or progesterone receptor-negative by IHC
- •PATIENT CHARACTERISTICS:
- •Menopausal status not specified
- •WHO performance status 0-2
- •Life expectancy > 3 months
- •ANC > 1.5 x 10^9/L
- •Platelet count > 100 x 10^9/L
- •Liver transaminases ≤ 3 times upper limit of normal (ULN)
- •Alkaline phosphatase ≤ 3 times ULN
- •Bilirubin ≤ 1.5 times ULN
- •Creatinine ≤ 2 times ULN
- •Not pregnant or nursing
- •Fertile patients must use effective contraception
- •No allergy to xylocaine
- •No heart failure, or kidney, bone marrow, respiratory, or liver insufficiency
- •PRIOR CONCURRENT THERAPY:
- •No prior first-line treatment for metastatic disease
排除标准
- 未提供
结局指标
主要结局
Changes in hormone receptor expression
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Biomarkers of Response to Taxotere in HRPC. ICORG 08-08, V2Metastatic CancerProstate CancerNCT01160705Cancer Trials Ireland73
已完成
不适用
Studying Tumor Tissue Samples to Learn More About DNA Changes and Response in Patients With Breast Cancer Treated With Bevacizumab on Clinical Trial ECOG-2100Breast CancerNCT00899418Eastern Cooperative Oncology Group500
已完成
不适用
SWOG 8897-A DNA Analysis in Predicting Treatment Outcome in Women With Breast Cancer in SWOG 8897Breast CancerNCT00896623SWOG Cancer Research Network1,577
终止
不适用
Plasma and Urine Samples From Patients With Hormone-Refractory Prostate Cancer Enrolled on Clinical Trials CALGB-9480 or CALGB-9583Prostate CancerNCT00898833Alliance for Clinical Trials in Oncology868
Unknown
不适用
Study of Blood and Urine Samples in Patients With Newly Diagnosed Localized Prostate Cancer Treated With Hormone Therapy and Radiation Therapy. ICORG 06-15Prostate CancerNCT00955435Cancer Trials Ireland60